Latest Property Portfolio News

Centuria Industrial REIT has expanded its exchangeable notes offering to $325 million, reflecting robust investor appetite, while simultaneously repurchasing nearly all its existing notes due 2028.

Australian Unity Office Fund reports a $35.6 million loss for FY25 as it advances asset disposals ahead of planned delisting, with the final property sale facing settlement uncertainty.

Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.

Cromwell Property Group reported a 15% drop in revenue and a 21% fall in operating profit for FY2025, yet significantly reduced its losses and net debt, signaling cautious progress amid challenging market conditions.

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

BluGlass Limited reported a 16% rise in revenue to $11.7 million for FY25, driven by key US Department of Defense contracts and new partnerships. However, the company’s net loss increased 8% to nearly $11 million amid ongoing R&D investment and operational scaling.

RAM Essential Services Property Fund (REP) posted a reduced net loss for FY25 alongside stable distributions and extended its debt facility to January 2027, maintaining a focus on essential healthcare and retail properties amid a cautious economic outlook.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

CVC Limited has reversed its fortunes with a $0.5 million net profit after tax for FY25, driven by strong property investment income and strategic land developments, while maintaining a cautious capital management approach and withholding dividends.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.